FREE
The free Clinical Research Planner — protocol snapshot with space for visit windows, daily clinical flow, PI signature tracking, and monitor-readiness checklists.
Download the free planner →Creatinine Clearance (CrCl) is a measure of how well a patient's kidneys are filtering waste from the blood. In clinical trials, CrCl is used as a proxy for the Glomerular Filtration Rate (GFR), the gold standard of kidney function, because it can be estimated from simple lab values without requiring a timed urine collection. For clinical research coordinators, CrCl is one of the most frequently calculated eligibility criteria, particularly in oncology, nephrology, and studies involving renally-cleared drugs.
The most widely used method for estimating CrCl is the Cockcroft-Gault equation, developed in 1976. Despite its age, it remains the standard formula referenced in the majority of FDA-approved drug labels and clinical trial inclusion/exclusion criteria — which is why most protocols specifically call for "CrCl per Cockcroft-Gault" rather than eGFR from a lab report.
The formula: CrCl (mL/min) = [(140 − Age) × Weight (kg)] / [72 × Serum Creatinine (mg/dL)], multiplied by 0.85 for female patients. The female correction factor accounts for lower baseline muscle mass and therefore lower creatinine production relative to men of the same weight.
Many investigational drugs are eliminated primarily by the kidneys. If a participant has impaired renal function, the drug may accumulate to toxic levels even at a standard dose. Protocols typically specify minimum CrCl thresholds (e.g., "CrCl ≥ 45 mL/min per Cockcroft-Gault") as an inclusion criterion. Some protocols also use CrCl brackets to define dose reduction tiers — participants with CrCl 30–60 may receive a reduced starting dose compared to those with CrCl > 60.
The Cockcroft-Gault formula was originally derived using actual body weight (ABW). However, in obese patients, using ABW can overestimate CrCl because excess adipose tissue does not produce creatinine proportionally. Many oncology protocols specify using Ideal Body Weight (IBW) or Adjusted Body Weight (AdjBW) in obese patients. Always follow your specific protocol's guidance, this detail is usually in the eligibility criteria or laboratory values section.
Creatinine clearance is one of the most calculated values in clinical research, and one of the most misapplied. The Cockcroft-Gault formula looks simple, and for the average patient it is. But the edge cases that exist around body weight selection, borderline values, unit discrepancies, and lab timing are precisely the situations that generate eligibility deviations. Understanding where the formula breaks down and how your protocol handles those situations is what prevents enrolling ineligible participants.
Modern clinical laboratories routinely report estimated GFR (eGFR) using the CKD-EPI equation, and many clinicians use eGFR in everyday practice. Yet the majority of clinical trial protocols, including trials opened in 2024 and 2025 — specify "CrCl per Cockcroft-Gault" rather than eGFR as the renal eligibility criterion. This is not an oversight.
Drug labels and clinical trial eligibility thresholds established over the past several decades were developed using Cockcroft-Gault. Switching to a different estimating equation would break comparability with the historical data that established those thresholds. The FDA expects the equation specified in the protocol — using a different equation without protocol authorization is a protocol deviation under FDA's December 2024 protocol deviations guidance. A CrCl of ≥45 mL/min per Cockcroft-Gault means something specific in the context of a drug's clinical development program, that threshold was validated against Cockcroft-Gault data, not CKD-EPI data. If your protocol says Cockcroft-Gault, using eGFR from the lab report, even if it's a "better" estimate of true GFR — is not protocol-compliant.
The most consequential judgment call in CrCl calculation is which weight to use, and it is also the most frequently mishandled. The original Cockcroft-Gault equation was derived using actual body weight (ABW). For patients within a normal weight range, ABW is the correct input. The complexity arises in obese patients.
Adipose tissue produces very little creatinine relative to lean body mass. When you use actual body weight in an obese patient, you are using a weight that is largely attributable to fat, which doesn't generate the creatinine that the formula is calibrated to. The result is an overestimate of CrCl, which can make a patient appear eligible when their true renal function would make them ineligible.
Most oncology protocols address this directly in the eligibility criteria or in the laboratory values section. Common approaches:
If your protocol does not specify which weight to use, that is a protocol ambiguity, not a license to default to whatever produces the most favorable result. Contact the sponsor's medical monitor before enrolling a patient where the weight choice affects eligibility. Document the clarification in the site file.
Rounding is a surprisingly common source of eligibility disputes. If a protocol specifies CrCl ≥ 45 mL/min and your calculation produces 44.8 mL/min, the patient does not meet the criterion, regardless of how close the value is. Clinical judgment about whether the patient "probably" has adequate renal function is not the standard. The protocol threshold is the standard.
Some protocols address rounding explicitly (e.g., "values may be rounded to the nearest whole number"). If yours does not, apply conventional rounding rules and document them. If rounding would bring a borderline value above the threshold, confirm the approach with the sponsor before proceeding — do not round up and enroll without documented sponsor concurrence.
Most protocols specify a timeframe for eligibility labs: "within 14 days prior to Day 1 dosing" or "within 28 days of informed consent." The creatinine used for your CrCl calculation must fall within this window. Verify both the draw date and the result date — results reported on Day −2 from a draw on Day −20 may be outside the specified window even though the result appears recent.
If a patient has multiple creatinine values within the eligibility window, use the most recent one. Do not average values or select the most favorable value — use the most current assessment of renal function. Document which value was used and its draw date in your eligibility worksheet or source documentation.
Eligibility CrCl determines whether a participant can enroll. What happens if their renal function deteriorates after enrollment is a separate protocol question, typically governed by dose modification guidelines or discontinuation criteria, not the initial eligibility threshold.
CRCs need to be alert to on-study creatinine values that fall below the enrollment threshold, because most protocols have specific dose modification or holding criteria based on worsening renal function. A participant who enrolled with CrCl of 62 mL/min and now has CrCl of 38 mL/min at Week 8 requires immediate PI review, whether that triggers a dose hold, reduction, or discontinuation depends on the protocol, but it is never simply ignored. Flag these values to the PI at the visit and document the clinical decision in source.
For every enrolled participant, your CrCl calculation documentation should include: the formula used (Cockcroft-Gault), the weight used and the rationale for that choice if not ABW, the creatinine value, its draw date, the patient's age and sex at the time of calculation, the calculated result, and whether the result meets the eligibility criterion. An undocumented CrCl calculation, where only the result is recorded and not the inputs — cannot be verified by a monitor or inspector and is a source documentation deficiency under 21 CFR 312.62.